DCTH
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Delcath Systems dosed the first patient in a Phase 2 trial of HEPZATO for liver-dominant metastatic breast cancerJul 9, 2026
- Delcath announced CHEMOSAT was included as a recommended liver-directed therapy in ESMO–EURACAN guidelines for uveal melanomaApr 6, 2026
- Delcath Systems announces publication of Phase 3 FOCUS study subgroup analyses in metastatic uveal melanomaDec 31, 2025
- Delcath Systems announces publication of real-world evidence supporting early use of liver-directed therapy with PHP in achieving long-term survival for metastatic uveal melanoma patientsNov 13, 2025
- Delcath Systems announces investigator-initiated CHOPIN Phase 2 trial presentation at ESMO 2025 CongressSep 23, 2025